Table 1.

Demographics and clinical details of all patients included in the study.

Patient	Age (years)	Gender	Time since diagnosis (years)	Genetic pathology	Medications
Patient 1	14.5	Female	14.5	Paternally inherited KCNJ11 mutation + interruption of Chromosome 1	Diazoxide
Patient 2	3.2	Female	3.0	Not identified	Diazoxide
Patient 3	12.3	Male	11.9	Not identified	Diazoxide
Patient 4	5.4	Male	5.4	Maternally inherited dominant ABCC8 mutation	Diazoxide
Patient 5	3.1	Male	3.1	Homozygous ABCC8 mutation	Octreotide
Patient 6	3.4	Female	3.4	Maternally inherited dominant ABCC8 mutation	Diazoxide
Patient 7	17.3	Male	17.1	GLUD1 mutation (de novo)	Diazoxide
Patient 8	13.3	Female	13.0	Homozygous HADH mutation	Diazoxide
Patient 9	17.7	Male	7.4	GCK mutation (inheritance not determined)	Diazoxide
Patient 10	2.1	Male	2.1	Heterozygous HNF4A partial deletion	Diazoxide

All patients continued on their mediactions for the duration of the study. Patient 6 withdrew from the study at the end of week 8 due to dissatisfaction with the CGM device.